Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032
Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032
The purpose of this study is to assess the effects of hepatic impairment on the multiple dose
 pharmacokinetics of BMS-650032.
Inclusion Criteria:

 -  Male and female subjects aged 18 to 70, with hepatic impairment conforming to
 Child-Pugh class A,B or C

 -  Each matched control subjects determined to be healthy

 Exclusion Criteria:

 -  History of esophageal and gastric bleeding within the past 6 months

 -  Primarily cholestatic liver disease

 -  Active alcoholic hepatitis

 -  Stable encephalopathy of ≥Stage 2

 -  Presence of severe ascites or edema

 -  Presence of hepatopulmonary or hepatorenal syndrome

 -  Positive for HIV

 -  Positive for HCV, unless HCV RNA is undetectable